scholarly article | Q13442814 |
P50 | author | Helena Käyhty | Q111990066 |
Merja Väkeväinen | Q124818481 | ||
Terhi Kilpi | Q124818485 | ||
Nina Ekström | Q124818494 | ||
P2093 | author name string | Jouko Verho | |
P2860 | cites work | A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers | Q73594815 |
Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies | Q74037367 | ||
Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT | Q74541105 | ||
Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood | Q77367132 | ||
Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conju | Q79162711 | ||
Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants | Q81012140 | ||
Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine | Q81104099 | ||
Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infants | Q24795590 | ||
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial | Q33557154 | ||
Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides | Q33867137 | ||
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers | Q33874664 | ||
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group | Q33896897 | ||
Efficacy of a pneumococcal conjugate vaccine against acute otitis media | Q33932973 | ||
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial | Q33986009 | ||
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants | Q34205630 | ||
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial | Q34220731 | ||
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia | Q34917765 | ||
Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. | Q35108576 | ||
Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells | Q35229917 | ||
Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide. | Q35428480 | ||
The Role of Antibody and Complement in the Reticuloendothelial Clearance of Pneumococci from the Bloodstream | Q40161697 | ||
Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media | Q44373346 | ||
Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae | Q44736820 | ||
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection | Q46198228 | ||
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine | Q46849891 | ||
Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine | Q47218152 | ||
Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines | Q48023963 | ||
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. | Q52039837 | ||
Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. | Q52041060 | ||
Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children | Q52051185 | ||
Pathogenesis of Pneumococcal Infection | Q59647738 | ||
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study | Q61622800 | ||
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity | Q64131545 | ||
Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group | Q68061882 | ||
Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b | Q68791967 | ||
Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production | Q70018803 | ||
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants | Q71072124 | ||
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants | Q71569665 | ||
Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates | Q72133190 | ||
Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae | Q73264844 | ||
Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B | Q73281054 | ||
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants | Q73298427 | ||
Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine | Q73402133 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Finland | Q33 |
antibody | Q79460 | ||
P304 | page(s) | 1794-1800 | |
P577 | publication date | 2007-01-29 | |
P1433 | published in | Infection and Immunity | Q6029193 |
P1476 | title | Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial | |
P478 | volume | 75 |
Q35867546 | A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice |
Q33825652 | Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo |
Q83981333 | Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization |
Q33601848 | Antibodies to the HMW1/HMW2 and Hia adhesins of nontypeable haemophilus influenzae mediate broad-based opsonophagocytic killing of homologous and heterologous strains |
Q86049387 | Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics |
Q47659427 | Determination of avidity of IgG against protein antigens from Streptococcus pneumoniae: assay development and preliminary application in clinical settings |
Q47841000 | IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants |
Q34738780 | Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines |
Q38875984 | Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults |
Q38443063 | Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose |
Q37130191 | Next generation protein based Streptococcus pneumoniae vaccines |
Q34444503 | Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age |
Q28394642 | Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine |
Q35136893 | Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance |
Q37316015 | Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. |
Q34998490 | Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness |
Q35868890 | Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. |
Q34170021 | Protein carriers of conjugate vaccines: characteristics, development, and clinical trials |
Q49568885 | Re-emergence of pneumococcal colonization by vaccine serotype 19F in persons aged ≥5 years after 13-valent pneumococcal conjugate vaccine introduction-Alaska, 2008-2013. |
Q33803550 | Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy |
Q40943510 | Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines |
Q34309712 | Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae |
Q46144154 | Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries |
Q24644461 | Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B |
Q37730648 | T cells control the generation of nanomolar-affinity anti-glycan antibodies |
Q38160248 | The history of pneumococcal conjugate vaccine development: dose selection |
Q28084920 | The host immune dynamics of pneumococcal colonization: implications for novel vaccine development |
Q37197138 | Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes |